Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Medical Genetics

Understanding the Biology and Diagnosis of NPC

At a Glance

Niemann-Pick disease type C (NPC) is diagnosed using a combination of blood biomarkers, genetic testing for NPC1 and NPC2 mutations, and sometimes a skin biopsy for filipin staining. These tests check for the abnormal buildup of cholesterol in cells that causes the disease.

Niemann-Pick Disease Type C (NPC) is often described as a cellular “traffic jam.” Understanding the biology behind this jam and the specialized tests used to find it can help you make sense of complex medical reports [1].

The Biology: A Broken Hand-off

To understand NPC, imagine your cells have a recycling center called a lysosome. Inside, fats like cholesterol must be sorted and sent back out to the cell to build healthy membranes. This requires a two-step “hand-off” between two proteins:

  1. NPC2: A small protein that acts like a “shuttle,” grabbing cholesterol inside the lysosome [2].
  2. NPC1: A larger protein that acts like an “exit ramp” in the lysosome wall [2][3].

In people with NPC, mutations in the NPC1 (about 95% of cases) or NPC2 genes break this system [4]. The cholesterol is “trapped” inside, unable to reach the exit ramp. This buildup eventually becomes toxic, leading to the symptoms seen in the liver, spleen, and brain [1][5].

How a Diagnosis is Made: The “Triple Check”

Because NPC is so rare and variable, doctors usually look for three pieces of evidence to confirm a diagnosis [6].

1. Blood Biomarkers (The First Clue)

Newer blood tests are now the preferred first-line screening because they are faster and less invasive than older methods [7].

  • Oxysterols (C-triol): These are “backup” fats that form when cholesterol can’t be processed normally. High levels of cholestane-3β,5α,6β-triol (often called C-triol) are a strong indicator of NPC1 [8].
  • Bile Acids (NPCBA2): Specific bile acids in the blood or urine can also point toward the disease [9][10].
  • Lyso-SM-509: A highly sensitive marker often used to confirm the diagnosis and monitor its severity [11].

2. Genetic Testing (The Blueprint)

Genetic testing looks for the specific mutations in your NPC1 or NPC2 genes [12].

  • Pathogenic/Likely Pathogenic: This means the mutation is known to cause the disease [4].
  • Variant of Uncertain Significance (VUS): This is a “maybe.” It means a mutation was found, but scientists aren’t sure yet if it causes the disease. In these cases, doctors rely more heavily on biomarkers and clinical signs [13][14].

3. Filipin Staining (The Functional Test)

Historically the “gold standard,” this test involves a skin biopsy. Scientists grow your cells in a lab and stain them with a fluorescent dye called filipin, which glows bright blue wherever cholesterol is trapped [14][15].

  • Classic Pattern: Shows heavy, obvious clusters of trapped cholesterol.
  • Intermediate/Variant Pattern: Shows some trapping, but less than usual. This is common in adult-onset or milder cases and often requires more testing to be sure [14][16].

Reading Your Reports

When you look at a genetic or pathology report, keep these terms in mind:

  • Autosomal Recessive: You typically need two mutations (one from each parent) to have the disease. This means that siblings of an affected individual have a 25% chance of also having the disease. It is highly recommended to seek genetic counseling for family members to discuss carrier testing and family risk [4].
  • Homozygous: Two identical disease-causing mutations were found.
  • Compound Heterozygous: Two different disease-causing (pathogenic) mutations were found (one on each copy of the gene) [17].
  • NTD (N-Terminal Domain): A specific part of the NPC1 protein often mentioned in reports because it is where the “hand-off” from NPC2 occurs [2].

Common questions in this guide

What blood tests are used to diagnose NPC?
Doctors use specialized blood tests to look for specific biomarkers, such as C-triol, bile acids, and Lyso-SM-509. High levels of these substances indicate that your cells are struggling to process cholesterol properly, which is a strong early clue for NPC.
What does it mean if my genetic test shows a Variant of Uncertain Significance (VUS)?
A VUS means a mutation was found in your NPC1 or NPC2 gene, but researchers are not entirely sure if it causes the disease. In these cases, your doctor will rely heavily on your blood biomarker levels and clinical symptoms to confirm the diagnosis.
What is the filipin staining test?
Filipin staining is a functional lab test performed on a skin biopsy. Scientists grow your cells in a lab and dye them with a fluorescent stain that glows bright blue if cholesterol is abnormally trapped inside, helping confirm how well your cells are functioning.
If my child is diagnosed with NPC, what is the risk for their siblings?
NPC is an autosomal recessive condition, meaning an affected person inherited a mutation from both parents. Because of this, siblings of an affected individual have a 25% chance of also having the disease. Genetic counseling is highly recommended for family members.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my (or my child's) report show two separate disease-causing mutations (compound heterozygous) or two of the same (homozygous)?
  2. 2.Is the 'VUS' (Variant of Uncertain Significance) on my report being re-evaluated in light of my recent blood biomarker levels?
  3. 3.Were the cholestane-3β,5α,6β-triol (C-triol) levels high enough to confirm a diagnosis even if the genetic testing was unclear?
  4. 4.If the filipin staining was 'intermediate' or 'variant,' what additional molecular testing do we need to reach a definitive answer?
  5. 5.How do these specific mutations correlate with the typical disease progression (infantile vs. adult-onset)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Structural Insight into Eukaryotic Sterol Transport through Niemann-Pick Type C Proteins.

    Winkler MBL, Kidmose RT, Szomek M, et al.

    Cell 2019; (179(2)):485-497.e18 doi:10.1016/j.cell.2019.08.038.

    PMID: 31543266
  2. 2

    Insights into the Molecular Mechanisms of Cholesterol Binding to the NPC1 and NPC2 Proteins.

    Cologna SM, Rosenhouse-Dantsker A

    Advances in experimental medicine and biology 2019; (1135()):139-160 doi:10.1007/978-3-030-14265-0_8.

    PMID: 31098815
  3. 3

    Clues to the mechanism of cholesterol transfer from the structure of NPC1 middle lumenal domain bound to NPC2.

    Li X, Saha P, Li J, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2016; (113(36)):10079-84 doi:10.1073/pnas.1611956113.

    PMID: 27551080
  4. 4

    The Spectrum of Niemann-Pick Type C Disease in Greece.

    Mavridou I, Dimitriou E, Vanier MT, et al.

    JIMD reports 2017; (36()):41-48 doi:10.1007/8904_2016_41.

    PMID: 28105569
  5. 5

    NPC1 regulates ER contacts with endocytic organelles to mediate cholesterol egress.

    Höglinger D, Burgoyne T, Sanchez-Heras E, et al.

    Nature communications 2019; (10(1)):4276 doi:10.1038/s41467-019-12152-2.

    PMID: 31537798
  6. 6

    Comprehensive Evaluation of Plasma 7-Ketocholesterol and Cholestan-3β,5α,6β-Triol in an Italian Cohort of Patients Affected by Niemann-Pick Disease due to NPC1 and SMPD1 Mutations.

    Romanello M, Zampieri S, Bortolotti N, et al.

    Clinica chimica acta; international journal of clinical chemistry 2016; (455()):39-45.

    PMID: 26790753
  7. 7

    Towards a New Diagnostic Standard for Niemann-Pick C Disease.

    Jiang X, Ory DS

    EBioMedicine 2016; (4()):18-9 doi:10.1016/j.ebiom.2016.01.004.

    PMID: 26981565
  8. 8

    A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease.

    Giese AK, Mascher H, Grittner U, et al.

    Orphanet journal of rare diseases 2015; (10()):78 doi:10.1186/s13023-015-0274-1.

    PMID: 26082315
  9. 9

    Diagnostic performance evaluation of sulfate-conjugated cholesterol metabolites as urinary biomarkers of Niemann-Pick disease type C.

    Maekawa M, Narita A, Jinnoh I, et al.

    Clinica chimica acta; international journal of clinical chemistry 2019; (494()):58-63 doi:10.1016/j.cca.2019.03.1610.

    PMID: 30876856
  10. 10

    Identification of novel bile acids as biomarkers for the early diagnosis of Niemann-Pick C disease.

    Mazzacuva F, Mills P, Mills K, et al.

    FEBS letters 2016; (590(11)):1651-62 doi:10.1002/1873-3468.12196.

    PMID: 27139891
  11. 11

    Clinical, biomarker and genetic spectrum of Niemann-Pick type C in Egypt: The detection of nine novel NPC1 mutations.

    Mahmoud IG, Elmonem MA, Elkhateeb NM, et al.

    Clinical genetics 2019; (95(4)):537-539 doi:10.1111/cge.13492.

    PMID: 30633340
  12. 12

    Patient with Niemann-Pick disease type C: over 20 years' follow-up.

    Abe K, Sakai N

    BMJ case reports 2017; (2017()) doi:10.1136/bcr-2017-220134.

    PMID: 28830896
  13. 13

    Reclassification of variants of uncertain significance in type I collagen genes: a national reference laboratory experience.

    Supari N, Baker D, Keigwin S, et al.

    Journal of medical genetics 2026; (63(5)):277-283 doi:10.1136/jmg-2025-111334.

    PMID: 41667232
  14. 14

    Laboratory diagnosis of Niemann-Pick disease type C: the filipin staining test.

    Vanier MT, Latour P

    Methods in cell biology 2015; (126()):357-75.

    PMID: 25665455
  15. 15

    A case of variant biochemical phenotype of Niemann-Pick disease type C accompanying savant syndrome.

    Hamatani M, Jingami N, Uemura K, et al.

    Rinsho shinkeigaku = Clinical neurology 2016; (56(6)):424-9 doi:10.5692/clinicalneurol.cn-000846.

    PMID: 27181747
  16. 16

    Molecular and biochemical biomarkers for diagnosis and therapy monitorization of Niemann-Pick type C patients.

    Hammerschmidt TG, de Oliveira Schmitt Ribas G, Saraiva-Pereira ML, et al.

    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 2018; (66()):18-23 doi:10.1016/j.ijdevneu.2017.11.007.

    PMID: 29197565
  17. 17

    A Niemann-Pick Disease Type C2 with Severe Pulmonary Involvement and Limited Therapeutic Options: A Case Report.

    Al-Shamrani A, Al-Shamrani K, Mahfoudh AB, et al.

    Children (Basel, Switzerland) 2022; (9(12)) doi:10.3390/children9121811.

    PMID: 36553254

This page provides educational information about the biology and diagnosis of Niemann-Pick disease type C (NPC). It is not a substitute for professional medical advice or formal genetic counseling.

Get notified when new evidence is published on Niemann-Pick disease type C.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.